phosphocreatine and Cardiotoxicity

phosphocreatine has been researched along with Cardiotoxicity* in 3 studies

Reviews

1 review(s) available for phosphocreatine and Cardiotoxicity

ArticleYear
Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.
    Reviews in cardiovascular medicine, 2017, Volume: 18, Issue:2

    The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer. The common cardiotoxic effects of doxorubicin include congestive heart failure and left ventricular dysfunction, and those of cyclophosphamide include pericarditis, myocarditis, and congestive heart failure. It has been postulated that cardiotoxicity of 5-fluorouracil presents as coronary artery diseases (eg, angina). Cardiomyopathy is a common outcome following treatment with the FAC regimen. We report on a 52-year-old woman with cardiomyopathy following chemotherapy and radiation therapy. The patient did not respond well to b-blockers and angiotensin-converting enzyme inhibitors. After the addition of exogenous phosphocreatine, the patient's cardiac condition improved significantly.

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Electrocardiography; Female; Fluorouracil; Humans; Middle Aged; Phosphocreatine; Tomography, X-Ray Computed; Treatment Outcome

2017

Other Studies

2 other study(ies) available for phosphocreatine and Cardiotoxicity

ArticleYear
Creatine phosphate disodium salt protects against Dox-induced cardiotoxicity by increasing calumenin.
    Medical molecular morphology, 2018, Volume: 51, Issue:2

    Inhibiting endoplasmic reticulum stress (ERS)-induced apoptosis may be a new therapeutic target in cardiovascular diseases. Creatine phosphate disodium salt (CP) has been reported to have cardiovascular protective effect, but its effects on ERS are unknown. The aim of this study was to identify the mechanism by which CP exerts its cardioprotection in doxorubicin (Dox)-induced cardiomyocytes injury. In our study, neonatal rats cardiomyocytes (NRC) was randomly divided into control group, model group, and treatment group. The cell viability and apoptosis were detected. grp78, grp94, and calumenin of the each group were monitored. To investigate the role of calumenin, Dox-induced ERS was compared in control and down-regulated calumenin cardiomyocytes. Our results showed that CP decreased Dox-induced apoptosis and relieved ERS. We found calumenin increased in Dox-induced apoptosis with CP. ERS effector C/EBP homologous protein was down-regulated by CP and it was influenced by calumenin. CP could protect NRC by inhibiting ERS, this mechanisms may be associated with its increasing of calumenin.

    Topics: Animals; Animals, Newborn; Apoptosis; Calcium-Binding Proteins; Cardiotonic Agents; Cardiotoxicity; Cells, Cultured; Doxorubicin; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Myocytes, Cardiac; Phosphocreatine; Rats; Transcription Factor CHOP

2018
The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury.
    Toxicology, 2015, Mar-02, Volume: 329

    Age is a known susceptibility factor for the cardiotoxicity of several anticancer drugs, including mitoxantrone (MTX). The impact of anticancer drugs in young patients is underestimated, thus we aimed to evaluate the cardiotoxicity of MTX in juvenile and adult animals. Juvenile (3 week-old) and adult (8-10 week-old) male CD-1 mice were used. Each group was treated with a 9.0mg/kg cumulative dose of MTX or saline; they were maintained in a drug-free period for 3-weeks after the last administration to allow the development of late toxicity (protocol 1), or sacrificed 24h after the last MTX administration to evaluate early cardiotoxicity (protocol 2). In protocol 1, no adult mice survived, while 2 of the juveniles reached the end of the protocol. High plasma aspartate aminotransferase/alanine aminotransferase ratio and a high cardiac reduced/oxidized glutathione ratio were found in the surviving MTX-treated juvenile mice. In protocol 2, a significant decrease in plasma creatine-kinase MB in juveniles was found 24h after the last MTX-administration. Cardiac histology showed that both MTX-treated populations had significant damage, although higher in adults. However, MTX-treated juveniles had a significant increase in fibrotic tissue. The MTX-treated adults had higher values of cardiac GSSG and protein carbonylation, but lower cardiac noradrenaline levels. For the first time, mature adult animals were shown to be more susceptible to MTX as evidenced by several biomarkers, while young animals appear to better adjust to the MTX-induced cardiac injury. Even so, the higher level of fibrotic tissue and the histological damage showed that MTX also causes cardiac damage in the juvenile population.

    Topics: Age Factors; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers; Body Weight; Cardiotoxicity; Caspase 3; Caspase 8; Caspase 9; Creatine; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Epinephrine; Fibrosis; Glutathione Disulfide; Heart; Heart Diseases; Kidney; Lipid Peroxidation; Liver; Male; Mice; Mitoxantrone; Myocardium; Norepinephrine; Organ Size; Phosphocreatine; Protein Carbonylation

2015